Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

CONTEXT: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). AIMS: To evaluate the efficacy of intravesical chemotherapy (IC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Urol Ann
Autors principals: Serretta, Vincenzo, Sommatino, Francesco, Gesolfo, Cristina Scalici, Franco, Vito, Cicero, Giuseppe, Allegro, Rosalinda
Format: Artigo
Idioma:Inglês
Publicat: Medknow Publications & Media Pvt Ltd 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4310111/
https://ncbi.nlm.nih.gov/pubmed/25657538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0974-7796.148582
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars